

In The Specification

On page 2, before line 1 of the application, please insert the following:

A²
--This application claims priority to co-pending patent application, Serial No. 09/662,270, filed on September 14, 2000, which is a divisional application of U.S. Serial No. 09/097,199, which issued as U.S. Patent 6,218,529 on April 17, 2001.

In the Claims

Please cancel claims 1-77, without prejudice or disclaimer.

Please add the following claims:

0974546-101001
A²
~~78.~~ A method of treating a patient with cancer comprising administering to the patient an effective amount of an agent that inhibits a peptide or polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

79. The method of claim 78, wherein the agent is an antibody.

80. The method of claim 79, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

81. The method of claim 80, wherein the antibody is a monoclonal antibody.

82. The method of claim 80 wherein the antibody is a polyclonal antibody.

83. The method of claim 80, wherein the antibody is conjugated to a radionucleotide.
84. The method of claim 80, wherein the antibody is linked to a chemotherapeutic agent.
85. The method of claim 78, wherein the cancer is bladder cancer, breast cancer or prostate cancer.

A² cont'd
86. The method of claim 78, wherein the agent inhibits SEQ ID NO: 3, SEQ ID NO: 83 or SEQ ID NO: 85 or a fragment thereof.

~~87.~~ A method of treating a cancer cell comprising administering to the cell an effective amount of an agent that inhibits a peptide or polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

88. The method of claim 87, wherein the agent is an antibody.

89. The method of claim 88, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

90. The method of claim 88, wherein the antibody is a monoclonal antibody.

91. The method of claim 88, wherein the antibody is a polyclonal antibody.

92. The method of claim 88, wherein the antibody is conjugated to a radionucleotide.

93. The method of claim 88, wherein the antibody is linked to a chemotherapeutic agent.

94. The method of claim 87, wherein the cell is in a patient.
